ArticleMolecular carcinogenesis2022

Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism.

Ritesh K Srivastava et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.